Clinical Trials Logo

Alpha-Mannosidosis clinical trials

View clinical trials related to Alpha-Mannosidosis.

Filter by:

NCT ID: NCT00668564 Terminated - Clinical trials for Niemann-Pick Disease, Type C

Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism

Start date: March 2008
Phase: Phase 2
Study type: Interventional

The primary objective of this clinical trial is to evaluate the ability to achieve and sustain donor engraftment in patients with lysosomal and peroxisomal inborn errors of metabolism undergoing hematopoietic stem cell transplantation (HCT).

NCT ID: NCT00498420 Completed - Alpha Mannosidosis Clinical Trials

The Natural History of Alpha-Mannosidosis

HUE-MAN
Start date: May 2007
Phase:
Study type: Observational

The natural history study of the rare lysosomal disease alpha-mannosidosis will answer the question; why the rare disease develops as it does?

NCT ID: NCT00176917 Completed - Clinical trials for Mucopolysaccharidosis I

Stem Cell Transplantation for Hurler

Start date: May 1999
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and engraftment of donor hematopoietic cells using this conditioning regimen in patients undergoing a hematopoietic (blood forming) cell transplant for Hurler syndrome, Maroteaux Lamy syndrome, Mannosidosis, or I-cell disease.

NCT ID: NCT00005900 Active, not recruiting - Clinical trials for Mucopolysaccharidosis I

Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Start date: August 1999
Phase: N/A
Study type: Observational

OBJECTIVES: I. Evaluate bronchoalveolar lavage fluid and serum obtained from pediatric patients with storage disorders prior to allogeneic hematopoietic stem cell transplantation (HSCT) for the presence of proinflammatory cytokines and for the production of nitric oxide by alveolar macrophages to identify possible risk factors for pulmonary complications. II. Investigate the underlying mechanism for the development of significant pulmonary complications in these patients during HSCT. III. Evaluate bronchoalveolar lavage fluid and serum obtained from these same patients at the time a pulmonary complication develops post-HSCT, or at 60 days post-HSCT if there has been no pulmonary complications.